Tab.2.
Drugs for hyperlipidemia in diabetes
| Drug | Target |
Clinical effects /availability |
Effect for TC/TG |
Limitation | Refs |
|---|---|---|---|---|---|
| Statin | HMG-CoA reductase | Extensively used Reduction of CVD |
Both | Increase CK Rhabdomyolysis |
5,104, 105 |
| Fibrate | PPARα | Reduction of CVD | TG | Rhabdomyolysis | 107 |
| Ezetimibe | intestinal NPC1L1 PPAR δ/β |
Short duration of action | TC | GI side effect | |
| Ecolocumab | PCSK9 | Familial hypercholesterolemia or high risk CVD patients |
TC | Need regular injection | 108,109 |
| ISIS 304801 | Antisense inhibition ApoC-III |
TG reduction 31.3-70.9% Under clinical trial |
TG | Need regular injection | 62,63 |
| CP-346086 JTT-130 |
MTP inhibitor | Underdevelopment | TG | 110,111 | |
| Ginko biloba | Lipoprotein(a) synthesis inhibition | Supplementary use | TC | 114-117 | |
| Tocilizumab | IL6 inhibition | Patients for rheumatoid arthritis | TC | 118-121 | |
| Torcetrapib Anacetrapib, Evacetrapib |
CETP inhibitor | Underdevelopment (anacetrapib, evacetrapib) |
TC | Blood pressure and serum aldosterone increased |
122 |
List of the drugs for hyperlipidemia in diabetes mellitus.
Only Statin, Fibrate, Ezetimibe and Evolocumabhave already widely in clinical use.
TC: total cholesterol; TG: triglyceride; CVD: cardiovascular disease; CK: creatinine kinase; GI: gastro intestinal tract.